HomeQuestion

For high-volume metastatic CRPC to bone, what dosing schedule of zoledronic acid or denosumab do you use?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?

For patients starting Pluvicto, do you have patients stop their ARPI?

How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate-risk prostate cancer?

When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?

What are the treatment options for a patient with unfavorable intermediate risk PCa who desires future child bearing?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.